flowchart TD
  A[Adult-type diffuse gliomas (infiltrating)] --> B{IDH1 / IDH2 mutation?}

  %% IDH-mutant branch
  B -->|Yes (IDH-mutant)| C{1p/19q codeletion?}
  C -->|Yes| O[Oligodendroglioma\nIDH-mutant & 1p/19q-codeleted\nWHO grade 2 or 3]
  C -->|No| AS[Astrocytoma\nIDH-mutant\nWHO grade 2, 3, or 4]

  %% Oligodendroglioma details
  O --> O1[Common molecular:\nTERT promoter mutation]
  O --> O2[ATRX retained\nTP53 usually wildtype]
  O --> O3[Grade 3 features:\nIncreased mitoses\nMicrovascular proliferation or necrosis may be present]

  %% Astrocytoma IDH-mutant details
  AS --> AS1[Common molecular:\nATRX loss\nTP53 mutation]
  AS --> AS2[WHO grade 4 if ANY:\nNecrosis\nMicrovascular proliferation\nCDKN2A/B homozygous deletion]
  AS --> AS3[Grade 2–3 based on histology:\nCellularity\nAnaplasia\nMitotic activity]

  %% IDH-wildtype branch
  B -->|No (IDH-wildtype)| D{GBM-defining molecular features?}
  D -->|Yes| GBM[Glioblastoma\nIDH-wildtype\nWHO grade 4]
  D -->|No| E[Diffuse astrocytoma\nIDH-wildtype\nNOS or NEC]

  %% GBM defining molecular features
  GBM --> G1[Upgrade to GBM if ANY:\nEGFR amplification\nTERT promoter mutation\nChromosome +7 / −10]
  GBM --> G2[Typical histology:\nNecrosis\nMicrovascular proliferation]
  GBM --> G3[Other common findings:\nPTEN loss\nCDKN2A/B deletion\nMGMT promoter methylation]

  %% If IDH-wt without GBM features
  E --> E1[Consider other entities:\nH3 K27-altered midline glioma\nH3 G34-mutant hemispheric glioma]
  E --> E2[Consider MAPK-altered gliomas\nPleomorphic xanthoastrocytoma]
  E --> E3[If incomplete workup:\nLabel as NOS or NEC]
